News

The company has submitted biologics license application (BLA) with to the FDA for its long-acting site-specifically PEGylated recombinant human factor VIII to treat Hemophilia A. BAY94-9027 has been

Alpha-synuclein (α-synuclein) is an aggregation-prone protein that contributes to the development of PD. This protein is the major constituent of Lewy bodies, which are pathological protein aggregates that

The AVERTS-1 trial was a 16-week, prospective, randomized, double-blind, placebo-controlled trial that enrolled a total of 165 patients with unilateral Ménière’s disease in the United States. The clinical

Claimed to be the first of its kind approval, the FDA has approved Kymriah to treat patients up to 25 years of age with B-cell precursor ALL, which

The ADC programs covered in the deal are IMGN779 and IMGN632 with an additional program also expected to be designated during the agreement term. While IMGN779 is a

Today, FORMA announced that Celgene has exercised its option, pursuant to the 2014 collaboration arrangement, to extend its strategic collaboration with FORMA by entering into a second collaboration

The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development option for tisotumab

Merck, along with the researchers in the clinical trial service unit at the University of Oxford, reported that anacetrapib has reduced the risk of major coronary events by

The CSL subsidiary will pay an upfront payment of $91m for the acquisition. CSL Behring will get to add a pre-clinical asset in CAL-H, an HSC gene therapy